2Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases(AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857～861.
4Liaw YF,Leung N,Guan R,Lau GK,Merican I; AsianPacific Consensus Working Parties on Hepatitis B.AsianPacific consensus statement on the management of chronic hepatitis B:an update.J Gastroenterol Hepatol,2003,18:239～245.
5Dienstag JD Cianciara J,Karayalcin S,Kowdley KV,Willems B,Plisek S,Woessner M,Gardner S,Schiff E.Durability of serologic response after lamivudine treatment of chronic hepatitis B.Hepatology,2003,37:748～755.
6Lee KM,Cho SW,Kim SW,Kim HJ,Hahm KB,Kim JH.Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion.J Viral Hepat,2002,9:208～212.
7Keeffe EB,Dieterich DT,Han SH,Jacobson IM,Martin P,Schiff ER,Tobias H,Wright TL.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.Clin Gastroenterol Hepatol,2004,2:87～106.
8Yuen MF,Wong DK,Sablon E,Tse E,Ng IO,Yuan H J,Siu CW,Sander TJ,Bourne E J,Hall JG,Condreay LD,Lai CL.HBsAg seroclearance in chronic hepatitis B in the Chinese:virological,histological,and clinical aspects.Hepatology,2004,39:1694～1701.Erratum in:Hepatol ogy,2004,40:767.
10Hsu HM, Lu CF, Lee SC, et al. Seroepidemiology surey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immuination. J Infect Dis, 1999,179:367-370.
5Wei Hou, Jian-Er Wo, Min-Wei Li and Ke-Zhou Liu Institute of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.In vitro cleavage of hepatitis B virus C mRNA by 10-23 DNA enzyme[J].Hepatobiliary & Pancreatic Diseases International,2005,4(4):573-576. 被引量：5
